Future Trends in CGT Regulation and What They Mean for Pipeline Planning Introduction to FDA Regulatory Pathways for Cell and Gene Therapies Understanding the regulatory landscape for cell and gene therapies (CGT) is essential for professionals in the biotech and pharmaceutical sectors. As these therapies become increasingly prominent in the healthcare field, particularly for rare diseases and genetic conditions, the FDA regulatory pathways for cell gene therapy CBER guidance will be crucial in the development of effective and compliant products. The Cell and Gene Therapy (CGT) sector is rapidly evolving, leading to new trends in regulatory practices that can significantly…

Common Missteps in Early CGT Interactions with CBER Reviewers Introduction to CBER’s Role in Cell and Gene Therapy Regulation Cell and gene therapies (CGTs) represent a new frontier in medical treatment, offering potential cures and innovative solutions for previously untreatable diseases. In the United States, the approval and regulation of CGTs fall under the jurisdiction of the Center for Biologics Evaluation and Research (CBER), a division of the Food and Drug Administration (FDA). Successful navigation of the FDA regulatory pathways for cell and gene therapy requires a firm understanding of CBER guidance and the common pitfalls encountered during preliminary interactions…

Regulatory intelligence tools to track evolving CGT guidance from CBER Regulatory Intelligence Tools to Track Evolving CGT Guidance from CBER The field of cell and gene therapy (CGT) is rapidly evolving, with regulatory frameworks being continuously updated to accommodate new technologies and methodologies. As professionals in regulatory affairs, clinical development, and quality assurance, understanding the nuances of the FDA regulatory pathways for cell and gene therapies, particularly those outlined by the Center for Biologics Evaluation and Research (CBER), is essential to ensuring compliance and successful product development. In this tutorial, we will outline the key steps and tools necessary to…

Governance Structures for Cross Functional CGT Regulatory Decision Making Effective governance in the regulatory landscape for cell and gene therapies (CGT) is critical for navigating the complex pathways defined by the US FDA, particularly under the auspices of the Center for Biologics Evaluation and Research (CBER). This tutorial provides a detailed, step-by-step guide aimed at regulatory leaders, CMC professionals, clinical teams, and quality assurance (QA) personnel involved in CGT product development. The emphasis will be on understanding and establishing optimal governance structures that facilitate robust regulatory decision-making, ensuring compliance with the FDA regulatory pathways for cell and gene therapies. Understanding…

Aligning Regulatory, CMC and Clinical Plans under the CGT Pathway Selected Cell and gene therapies (CGTs) represent a transformative approach to treating or potentially curing diseases that previously lacked effective treatments. However, navigating the complex regulatory landscape set forth by the FDA can be challenging. This article provides a step-by-step tutorial on how to align regulatory, Chemistry, Manufacturing, and Controls (CMC), and clinical plans under the chosen CGT pathway based on the CBER guidance from the FDA. Understanding the Regulatory Landscape for CGTs The FDA regulates CGT products primarily through the Center for Biologics Evaluation and Research (CBER). Understanding the…